Evidence map›Paper›PMID 19930006›Full record

Trial reportDiabetes, obesity & metabolism2009

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.

J Jendle, M A Nauck, D R Matthews, A Frid, K Hermansen, M Düring, M Zdravkovic, B J Strauss, A J Garber, LEAD-2 and LEAD-3 Study Groups

3 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00294723. Cited by 122 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed, 9 pooled it
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00294723 phase3terminated

Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes

Ran2006Enrolled746Registered outcomes17Posted comparisons45ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsGlimepiride, liraglutide, Placebo
PMID 21883806PMID 23010561PMID 22055210PMID 26574791PMID 22174428PMID 26936426PMID 22193143PMID 19491536PMID 25504028PMID 23186975PMID 21450987PMID 18819705other papers from this trial
Open the trial in the graph
NCT00318461 phase3completed

Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes

Ran2006Enrolled1,091Registered outcomes14Posted comparisons74ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsGlimepiride, liraglutide, Metformin, Placebo
PMID 21883806PMID 19491535PMID 23010561PMID 22055210PMID 21883438PMID 18931095PMID 22193143PMID 19491536PMID 25504028PMID 23186975PMID 21450987PMID 22985213other papers from this trial
Open the trial in the graph
NCT01761318 phase4completedstarted 2013, after this paper: background citation

Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus

Ran2013Enrolled50Registered outcomes48Posted comparisons0ConditionsCardiovascular Disease, Diabetes Mellitus Type 2, Diastolic Dysfunction, Fatty LiverArmsliraglutide, Liraglutide - Placebo
PMID 16776751PMID 18819705PMID 19915017PMID 19349323PMID 11997279PMID 19815124PMID 20609967PMID 22586279PMID 22723560PMID 22949540PMID 19540343PMID 19317822other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 9 syntheses or guidelines pooled it, 297 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 6 countries.

J JendleFaculty of Health Science, Orebro University, Orebro, Sweden. Johan.Jendle@liv.se
M A Nauck
D R Matthews
A Frid
K Hermansen
M Düring
M Zdravkovic
B J Strauss
A J Garber
LEAD-2 and LEAD-3 Study Groups
Novo Nordisk (Denmark) · DKÖrebro University · SEAarhus University · DKBaylor College of Medicine · USDiabeteszentrum Bad Lauterberg · DEMonash University · AUOxford BioMedica (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe effect on body composition of liraglutide, a once-daily human glucagon-like peptide-1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D).

methodsThese were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3). Patients with T2D, aged 18-80 years, body mass index (BMI) < or =40 kg/m(2) (LEAD-2), < or =45 kg/m(2) (LEAD-3) and HbA1c 7.0-11.0% were included. Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3. LEAD-2/3: total lean body tissue, fat tissue and fat percentage were measured. LEAD-2: adipose tissue area and hepatic steatosis were assessed.

resultsLEAD-2: fat percentage with liraglutide 1.2 and 1.8 mg/metformin was significantly reduced vs. glimepiride/metformin (p < 0.05) but not vs. placebo. Visceral and subcutaneous adipose tissue areas were reduced from baseline in all liraglutide/metformin arms. Except with liraglutide 0.6 mg/metformin, reductions were significantly different vs. changes seen with glimepiride (p < 0.05) but not with placebo. Liver-to-spleen attenuation ratio increased with liraglutide 1.8 mg/metformin possibly indicating reduced hepatic steatosis. LEAD-3: reductions in fat mass and fat percentage with liraglutide monotherapy were significantly different vs. increases with glimepiride (p < 0.01).

conclusionLiraglutide (monotherapy or added to metformin) significantly reduced fat mass and fat percentage vs. glimepiride in patients with T2D.

Indexed as

AdolescentAdultAgedAged, 80 and overBody CompositionBody WeightDelayed-Action PreparationsDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlucagon-Like Peptide 1Glycated HemoglobinHumansHypoglycemic AgentsLiraglutideMaleDelayed-Action PreparationsglimepirideGlucagon-Like Peptide 1Glycated HemoglobinHypoglycemic AgentsLiraglutideSulfonylurea Compounds

Identifiers

PMID19930006
OpenAlexW2022271042

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.